目次

Table of Contents

Executive Summary
Market Overview

Market Landscape
Market ecosystem
Value chain analysis

Market Sizing
Market definition
Market segment analysis
Market size 2020
Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
Five forces summary
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

Market Segmentation by Drug class
Market segments
Comparison by Drug class
Beta blockers - Market size and forecast 2020-2025
ARBs - Market size and forecast 2020-2025
ACE inhibitors - Market size and forecast 2020-2025
Others - Market size and forecast 2020-2025
Market opportunity by Drug class

Customer landscape

Geographic Landscape
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2020-2025
Europe - Market size and forecast 2020-2025
Asia - Market size and forecast 2020-2025
ROW - Market size and forecast 2020-2025
Key leading countries
Market opportunity By Geographical Landscape
Market drivers
Market challenges
Market trends

Vendor Landscape
Vendor landscape
Landscape disruption
Vendor landscape

Vendor Analysis
Vendors covered
Market positioning of vendors
Amgen Inc.
AstraZeneca Plc
Bayer AG
Bristol-Myers Squibb Co.
Daiichi Sankyo Co. Ltd.
Eli Lilly and Co.
Exelixis Inc.
Gilead Sciences Inc.
Novartis AG
Pfizer Inc.

Appendix
Scope of the report
Currency conversion rates for US$
Research methodology
List of abbreviations

1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2020 - 2025 ($ million)
13: Global market: Year-over-year growth 2020 - 2025 (%)
14: Five forces analysis 2020 & 2025
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2020
21: Drug class - Market share 2020-2025 (%)
22: Comparison by Drug class
23: Beta blockers - Market size and forecast 2020-2025 ($ million)
24: Beta blockers - Year-over-year growth 2020-2025 (%)
25: ARBs - Market size and forecast 2020-2025 ($ million)
26: ARBs - Year-over-year growth 2020-2025 (%)
27: ACE inhibitors - Market size and forecast 2020-2025 ($ million)
28: ACE inhibitors - Year-over-year growth 2020-2025 (%)
29: Others - Market size and forecast 2020-2025 ($ million)
30: Others - Year-over-year growth 2020-2025 (%)
31: Market opportunity by Drug class
32: Customer landscape
33: Market share By Geographical Landscape 2020-2025 (%)
34: Geographic comparison
35: North America - Market size and forecast 2020-2025 ($ million)
36: North America - Year-over-year growth 2020-2025 (%)
37: Europe - Market size and forecast 2020-2025 ($ million)
38: Europe - Year-over-year growth 2020-2025 (%)
39: Asia - Market size and forecast 2020-2025 ($ million)
40: Asia - Year-over-year growth 2020-2025 (%)
41: ROW - Market size and forecast 2020-2025 ($ million)
42: ROW - Year-over-year growth 2020-2025 (%)
43: Key leading countries
44: Market opportunity By Geographical Landscape ($ million)
45: Impact of drivers and challenges
46: Vendor landscape
47: Landscape disruption
48: Industry risks
49: Vendors covered
50: Market positioning of vendors
51: Amgen Inc. - Overview
52: Amgen Inc. - Business segments
53: Amgen Inc. - Key offerings
54: Amgen Inc. - Key customers
55: Amgen Inc. - Segment focus
56: AstraZeneca Plc - Overview
57: AstraZeneca Plc - Product and service
58: AstraZeneca Plc - Key offerings
59: AstraZeneca Plc - Key customers
60: AstraZeneca Plc - Segment focus
61: Bayer AG - Overview
62: Bayer AG - Business segments
63: Bayer AG - Key offerings
64: Bayer AG - Key customers
65: Bayer AG - Segment focus
66: Bristol-Myers Squibb Co. - Overview
67: Bristol-Myers Squibb Co. - Product and service
68: Bristol-Myers Squibb Co. - Key offerings
69: Bristol-Myers Squibb Co. - Key customers
70: Bristol-Myers Squibb Co. - Segment focus
71: Daiichi Sankyo Co. Ltd. - Overview
72: Daiichi Sankyo Co. Ltd. - Business segments
73: Daiichi Sankyo Co. Ltd. - Key offerings
74: Daiichi Sankyo Co. Ltd. - Key customers
75: Daiichi Sankyo Co. Ltd. - Segment focus
76: Eli Lilly and Co. - Overview
77: Eli Lilly and Co. - Business segments
78: Eli Lilly and Co. - Key offerings
79: Eli Lilly and Co. - Key customers
80: Eli Lilly and Co. - Segment focus
81: Exelixis Inc. - Overview
82: Exelixis Inc. - Business segments
83: Exelixis Inc. - Key offerings
84: Exelixis Inc. - Key customers
85: Exelixis Inc. - Segment focus
86: Gilead Sciences Inc. - Overview
87: Gilead Sciences Inc. - Product and service
88: Gilead Sciences Inc. - Key offerings
89: Gilead Sciences Inc. - Key customers
90: Gilead Sciences Inc. - Segment focus
91: Novartis AG - Overview
92: Novartis AG - Business segments
93: Novartis AG - Key offerings
94: Novartis AG - Key customers
95: Novartis AG - Segment focus
96: Pfizer Inc. - Overview
97: Pfizer Inc. - Business segments
98: Pfizer Inc. - Key offerings
99: Pfizer Inc. - Key customers
100: Pfizer Inc. - Segment focus
101: Currency conversion rates for US$
102: Research Methodology
103: Validation techniques employed for market sizing
104: Information sources
105: List of abbreviations